Response Genetics

Cancer Genetics gets approval to buy Response Genetics

Thursday, October 8, 2015

Cancer Genetics, a DNA-based cancer diagnostics provider, has received approval from the U.S. bankruptcy court in Delaware to purchase substantially all of the assets of Los Angeles-based Response Genetics Inc. (RGI), a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. CGI also agreed to assume some of RGI’s liabilities. The sale is subject to certain customary closing conditions and is expected to close by Oct. 9.

[Read More]

Codexis appoints David O’Toole as CFO

Wednesday, September 5, 2012

Codexis, a Redwood City, Calif.-based developer of cost-advantaged processes for the production of biofuels, bio-based chemicals and pharmaceuticals, has appointed David O’Toole as senior vice president and CFO.

[Read More]

Two GSK melanoma drugs garner top results

Monday, June 4, 2012

GlaxoSmithKline released results from two of its phase III melanoma studies: one evaluating single agent therapy with the targeted anti-cancer agents, dabrafenib and trametinib, in patients with BRAF V600 mutation positive metastatic melanoma; and one evaluating trametinib alone.

[Read More]